{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:45:17Z","timestamp":1786538717316,"version":"build-2736575974"},"reference-count":19,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      While osimertinib is the standard of care for\n                      <jats:italic>EGFR<\/jats:italic>\n                      -mutated advanced non-small cell lung cancer (NSCLC), acquired resistance is inevitable. Resistance mechanisms involving the simultaneous activation of dual bypass pathways, coupled with the complete loss of the primary\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutation, are exceptionally rare and pose significant therapeutic challenges.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report a clinically instructive case of a 64-year-old female with stage IV lung adenocarcinoma initially harboring an\n                      <jats:italic>EGFR<\/jats:italic>\n                      exon 19 deletion. She received uninterrupted first-line osimertinib for approximately five years, with good tolerability and no dose reduction or treatment interruption. During follow-up, a small asymptomatic central nervous system (CNS) oligoprogressive lesion was initially managed with continued osimertinib and close brain magnetic resonance imaging (MRI) surveillance because extracranial disease remained controlled. CyberKnife stereotactic radiosurgery (SRS) was subsequently performed after lesion enlargement, followed by systemic thoracic progression. A repeat biopsy, analyzed via immunohistochemistry and comprehensive next-generation sequencing, revealed a molecularly distinct clonal shift characterized by the simultaneous emergence of an\n                      <jats:italic>EML4-ALK<\/jats:italic>\n                      fusion and a\n                      <jats:italic>BRAF<\/jats:italic>\n                      V600G mutation, accompanied by the complete clearance of the original\n                      <jats:italic>EGFR<\/jats:italic>\n                      mutation. Confronted with this unique clonal evolution, the patient was transitioned to monotherapy with the third-generation ALK tyrosine kinase inhibitor (TKI) lorlatinib. This targeted intervention was associated with rapid regression of the thoracic lesions, while a reduction in the previously irradiated intracranial lesion was also observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      To our knowledge, this is the first documented case of concurrent acquisition of an\n                      <jats:italic>EML4-ALK<\/jats:italic>\n                      fusion and a\n                      <jats:italic>BRAF V600G<\/jats:italic>\n                      mutation after five years of first-line osimertinib therapy, in which the\n                      <jats:italic>ALK<\/jats:italic>\n                      fusion was prioritized as the predominant actionable driver. This case highlights the importance of longitudinal re-biopsy and comprehensive molecular profiling to distinguish conventional EGFR-TKI resistance from molecularly distinct clonal replacement or oncogenic driver switching after prolonged targeted therapy.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1919298","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:26:31Z","timestamp":1786537591000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Acquired EML4-ALK fusion and BRAF V600G dual bypass activation following osimertinib resistance in lung adenocarcinoma and successful treatment with lorlatinib: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Rui","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The Fourth Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","unstructured":"NCCN Clinical Practice Guidelines in Oncology: non-Small Cell Lung Cancer Version 3. 2026\n          \n          \n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030146","article-title":"Lung cancer: targeted therapy in 2025","volume":"32","author":"Bouchard","year":"2025","journal-title":"Curr Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-16-0407","article-title":"Characterization of EGFR T790M, L792F, and C797S mutations as mechanisms of acquired resistance to afatinib in lung cancer","volume":"16","author":"Kobayashi","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.12496","article-title":"Patient harboring a novel PIK3CA point mutation after acquired resistance to crizotinib in an adenocarcinoma with ROS1 rearrangement: a case report and literature review","volume":"8","author":"Xu","year":"2017","journal-title":"Thorac Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1308313","article-title":"Clinical and molecular profiling of EGFR-mutant lung adenocarcinomas transformation to small cell lung cancer during TKI treatment","volume":"13","author":"Chen","year":"2023","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.92202","article-title":"Anaplastic lymphoma kinase (ALK) fusion as a resistance mechanism to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors with complete response after osimertinib and alectinib: a case report and literature review","volume":"17","author":"Cheung","year":"2025","journal-title":"Cureus"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.14291","article-title":"Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion","volume":"13","author":"Yin","year":"2022","journal-title":"Thorac Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3892\/ol.2025.15144","article-title":"Rare sequential EGFR and ALK mutations in non-small cell lung cancer: a case report and literature review","volume":"30","author":"Nguyen","year":"2025","journal-title":"Oncol Lett"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000001275","article-title":"Targeted therapies in non-small cell lung cancer: a contemporary review","author":"Abdelmonem","year":"2025","journal-title":"Am J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02641","article-title":"AENEAS: a randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1584-8","article-title":"Clinicopathologic characteristics of ALK rearrangements in primary lung adenocarcinoma with identified EGFR and KRAS status","volume":"140","author":"Wang","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.027","article-title":"Receptor tyrosine kinase fusions and BRAF kinase fusions are rare but actionable resistance mechanisms to EGFR tyrosine kinase inhibitors","volume":"13","author":"Schrock","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1390523","article-title":"Therapeutic strategies to overcome ALK-fusion and BRAF-mutation as acquired resistance mechanism in EGFR-mutated non-small cell lung cancer: two case reports","volume":"14","author":"Zeng","year":"2024","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3892\/or.2020.7851","article-title":"Safety and efficacy of anaplastic lymphoma kinase tyrosine kinase inhibitors in non-small cell lung cancer (review)","volume":"45","author":"Wang","year":"2021","journal-title":"Oncol Rep"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.02.021","article-title":"First-line lorlatinib versus crizotinib in Asian patients with advanced ALK-positive NSCLC: five-year outcomes from the CROWN study","volume":"20","author":"Wu","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000030913","article-title":"Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib","volume":"101","author":"Guo","year":"2022","journal-title":"Med (Baltimore)"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.21037\/apm-22-744","article-title":"Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report","volume":"11","author":"Ren","year":"2022","journal-title":"Ann Palliat Med"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.71749","article-title":"A case of lung adenocarcinoma with concurrent EGFR mutation and ALK fusion combined with literature review","volume":"14","author":"Chen","year":"2026","journal-title":"Clin Case Rep"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1919298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:26:36Z","timestamp":1786537596000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1919298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":19,"alternative-id":["10.3389\/fonc.2026.1919298"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1919298","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1919298"}}